Fink, Emma C.

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 863

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome

Donovan, K. A., An, J., Nowak, R. P., Yuan, J. C., Fink, E. C., Berry, B. C., Ebert, B. L., & Fischer, E. S. (2018) · eLife

Congenital limb and hand anomaliesDevelopmental Biology and Gene Regulation

Cited by 509

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 433

The novel mechanism of lenalidomide activity

Fink, E. C., & Ebert, B. L. (2015) · Blood

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 213

Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice

Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 131

Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia

Järås, M., Miller, P. G., Chu, L. P., Puram, R. V., Fink, E. C., Schneider, R. K., Al-Shahrour, F., Peña, P., Breyfogle, L. J., Hartwell, K. A., et al. (2014) · Journal of Experimental Medicine

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 92